You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
When we receive a report of a potential adverse drug reaction, the report will be entered into the Lundbeck Safety Database and it will be evaluated by a team of medical doctors, nurses and pharmacists. In case of any ambiguity or missing information in the report, we are obliged to contact the reporter for additional information. If the report is received from a patient, we will ask for permission to contact the patient’s doctor, nurse or pharmacist to confirm the provided information and potentially also request additional relevant information to enable us to assess the case.
Adverse drug reaction reports will be reported as individual cases to worldwide health authorities and also be included in cumulative reports according to national legislation and requirements. In addition, they will be included in the ongoing monitoring for new signals that will help us to identify potential new risks associated with our products. Patient information and other personal data reported to Lundbeck will be further processed in an anonymised manner according to current data protection laws.
If you experience a potential adverse drug reaction, please consult your doctor, nurse or pharmacist for advice.
If you wish to report an adverse drug reaction, side-effect or other safety issue with a Lundbeck product, please forward your message to SafetyLuUnitedKingdom@lundbeck.com or telephone 01908 638972.
Alternatively you may use the online contact form by clicking below.
Please note that that we may contact you to follow-up on the information provided.
Lundbeck has developed some of the world’s most widely
prescribed therapies for brain diseases.
How we register clinical trial protocols and disclose results of clinical trials.
Get in touch with us at our headquarters or a local affiliate office.
UK-NOTPR-0643 | April 2022